Big Plans and 40 Years of Experience
News Jun 30, 2015
Rudi Vollmer (61) has become the new Technical Managing Director of Greiner Bio-One GmbH. Vollmer, formerly head of production at the Frickenhausen site, replaces Rainer Perneker, who has left the management team in Germany to focus on the business as Divisional Manager of the Greiner Bio-One International GmbH.
As a member of the Greiner Bio-One GmbH Germany management team, Rudi Vollmer is now responsible for production and technology. Heinz Schmid stays as head of the sales division and the management spokesperson. Georg Heftberger remains responsible for commercial and business operations. “I have extensive plans for working with the other two Managing Directors to build the success of Greiner Bio-One GmbH in Frickenhausen,” says Vollmer, whose responsibilities also cover the key areas of quality management, project management and design.
Anniversary - total of 40 years with Greiner
Rudi Vollmer started his career at Greiner (Labortechnik) in Nürtingen in 1975 - in the field of toolmaking. In 1978, he qualified and was taken on as a production foreman. He moved to the newly built site in Frickenhausen in 1988, where he took over management of the high-throughput screening and immunology production divisions three years later. When project management was introduced in March 2006, Rudi Vollmer took on full management of production. He celebrated 40 years at the company in April 2015.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE